Surfactant for the Treatment of ARDS in a Patient With COVID-19.


Journal

Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335

Informations de publication

Date de publication:
07 2021
Historique:
received: 09 07 2020
revised: 03 12 2020
accepted: 02 01 2021
pubmed: 26 1 2021
medline: 21 7 2021
entrez: 25 1 2021
Statut: ppublish

Résumé

Patients with COVID-19 report severe respiratory symptoms consistent with ARDS. The clinical presentation of ARDS in COVID-19 is often atypical, as patients with COVID-19 exhibit a disproportionate hypoxemia compared with relatively preserved lung mechanics. This pattern is more similar to neonatal respiratory distress syndrome secondary to surfactant deficiency, which has been shown to benefit from exogenous surfactant. We present our experience with exogenous surfactant treatment in a patient with COVID-19 experiencing COVID-19-related ARDS. The patient responded with improved oxygenation, and we believe surfactant was the catalyst for the successful extubation and clinical improvement of the patient.

Identifiants

pubmed: 33493441
pii: S0012-3692(21)00100-8
doi: 10.1016/j.chest.2021.01.028
pmc: PMC7825915
pii:
doi:

Substances chimiques

Antiviral Agents 0
Biological Products 0
Pulmonary Surfactants 0
calfactant Q4K217VGA9

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

e9-e12

Informations de copyright

Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Références

N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Chest. 2015 Aug;148(2):356-364
pubmed: 25855884
Pediatr Res. 2017 Jan;81(1-2):240-248
pubmed: 27706130
Transplantation. 2008 Dec 15;86(11):1554-9
pubmed: 19077889
Am J Respir Crit Care Med. 2020 Aug 15;202(4):624-626
pubmed: 32579022
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Sci Rep. 2020 Nov 10;10(1):19395
pubmed: 33173052
Crit Care. 2020 May 6;24(1):198
pubmed: 32375845
Am J Respir Crit Care Med. 2020 May 15;201(10):1299-1300
pubmed: 32228035
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620951043
pubmed: 32865137
BMC Pulm Med. 2019 Jan 9;19(1):9
pubmed: 30626363
Front Med (Lausanne). 2020 May 22;7:254
pubmed: 32574339
Respir Res. 2020 Jul 28;21(1):198
pubmed: 32723327
N Engl J Med. 2004 Aug 26;351(9):884-92
pubmed: 15329426
Am J Physiol Lung Cell Mol Physiol. 2020 Jul 1;319(1):L115-L120
pubmed: 32493030
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Crit Care. 2020 Sep 7;24(1):552
pubmed: 32894160
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
J Biol Chem. 2019 Mar 22;294(12):4282-4289
pubmed: 30733339

Auteurs

Moshe Heching (M)

Beilinson Hospital, Pulmonary Department, Rabin Medical Center Petach Tikva, Israel. Electronic address: moshehe@clalit.org.il.

Shaul Lev (S)

Sharon Hospital, Intensive Care Department, Rabin Medical Center, Petach Tikva, Israel.

Dorit Shitenberg (D)

Beilinson Hospital, Pulmonary Department, Rabin Medical Center Petach Tikva, Israel.

Dror Dicker (D)

Sharon Hospital, Intensive Care Department, Rabin Medical Center, Petach Tikva, Israel.

Mordechai R Kramer (MR)

Beilinson Hospital, Pulmonary Department, Rabin Medical Center Petach Tikva, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH